Skip to main content
. 2017 Apr 4;17:242. doi: 10.1186/s12879-017-2356-2

Table 1.

Characteristics of the study population, overall and by seropositivity for anti-PT IgG

Total (n = 1999) Seropositivea (n = 295) Seronegativeb (n = 1704)
Demographics
 Age (years) 47.4 ± 17.7 48.8 ± 19.4 47.1 ± 17.4
 Female 1212/1999 (60.6) 160/295 (54.2) 1052/1704 (61.7)
Pertussis-related history
 Pertussis vaccination 882/1163 (75.8) 127/165 (77.0) 755/998 (75.7)
 Prior pertussis 88/1566 (5.6) 15/227 (6.6) 73/1339 (5.5)
  Infant 3/87 (3.4) 0 3/73 (4.1)
  Child 75/87 (86.2) 13/14 (92.9) 62/73 (84.9)
  Adolescent 3/87 (3.4) 1/14 (7.1) 2/73 (2.7)
  Adult 6/87 (6.9) 0 6/73 (8.2)
 Long-lasting coughc 164/1971 (8.3) 20/290 (6.9) 144/1681 (8.6)
 Recent contact with a person with pertussis/long-lasting coughc 227/1795 (12.6) 30/270 (11.1) 197/1525 (12.9)
 Regular contact with children 919/1999 (46.0) 122/295 (41.4) 797/1704 (46.8)
 Relevant medicationsd 241/1962 (12.3) 39/287 (13.6) 202/1675 (12.1)
 Relevant hospitalizationse 10/1994 (0.5) 4/294 (1.4) 6/1700 (0.4)

Data are mean ± SD or n/N (%), where N is the number of subjects with known data

Abbreviations: Anti-PT IgG anti-pertussis toxin immunoglobulin G, OD optical density, SD standard deviation

a>0.3 OD units

b≤0.3 OD units

cLasting ≥3 weeks in the previous 12 months

dAny antibiotics and/or other medication (i.e., any cough medicines) for lower respiratory tract infections or (suspected) pertussis infections in the previous 12 months

eHospitalized due to respiratory infections in the previous 12 months